Table 4.

Summary of antidrug antibody status: safety analysis set

	F-F-F N=216 n (%)	F-RP-F N=108 n (%)	RP-F-F N=108 n (%)	RP-RP-F N=213 n (%)
Period 2, Week 0
Total	216	108	108	212
Positive	133 (61.6)	69 (63.9)	67 (62.0)	123 (58.0)
Week 12
Total	202	103	103	202
Positive	107 (53.0)	60 (58.3)	54 (52.4)	101 (50.0)
Week 24
Total	197	100	96	199
Positive	99 (50.3)	58 (58.0)	47 (49.0)	100 (50.3)
Period 3, Week 30*
Total	187	100	93	190
Positive	97 (51.9)	61 (61.0)	42 (45.2)	98 (51.6)
Week 54
Total	181	93	89	181
Positive	103 (56.9)	49 (52.7)	41 (46.1)	77 (42.5)
Week 76
Total	176	90	81	174
Positive	90 (51.1)	49 (54.4)	39 (48.1)	74 (42.5)
Week 80
Total	173	87	80	170
Positive	91 (52.6)	48 (55.2)	37 (46.3)	72 (42.4)

*Week 30 is end of Period 2.

Percentages are based on the number of patients in the safety analysis set with an assay result obtained at each planned relative time (Week).

F, FKB327; N, number of patients in the safety analysis set; n, total number of patients with observation; RP, reference product.